施普善在急性脑梗死治疗中的应用

目的：观察不同剂量的施普善对急性脑梗死患者疗效的差异。方法：将2009年3月～2011年3月在本院住院或门诊治疗的150例急性脑梗死患者,随机分为小剂量组、中剂量组和大剂量组,3组各50例,均应用施普善联合阿司匹林、辛伐他汀治疗,小剂量组应用施普善10ml/d,中剂量组应用施普善30ml/d,大剂量组应用施普善50ml/d,分别于发病后48h内、治疗20d后对3组患者进行神经功能缺损程度评分和临床疗效评定,比较3组的疗效差异。结果：治疗后3组神经功能缺损程度评分均有明显改善,大剂量组优于中剂量组（P〈0.05）,中剂量组优于小剂量组（P〈0.05）;治疗后3组临床疗效比较,大剂量组高于中剂量组,中剂量组高于小剂量组。结论：施普善应用于急性脑梗死治疗有效,且在一定剂量范围内,疗效与剂量呈正相关。

Application of cerebroprotein hydrolysate in treatment of acute cerebral infarction

Objective：To observe the differences of cerebroprotein hydrolysate（Cerebrolysin） in treatment of acute cerebral infarction patients with different dose.Methods：150 cases of acute cerebral infarction were divided into three groups randomly,each of them were treated with cerebroprotein hydrolysate that combined with aspirin,simvastatin,low-dose group received cerebroprotein hydrolysate 10 ml/day,medium-dose group received it 30 ml/day,high-dose group received it 50 ml/day.Neurologic impairment score and curative effect were evaluated and compared within 48 hours after the onset and 20 days after treatments among the three groups.Results：After treatment,three groups＇ neurologic scores had improved significantly,high-dose group was superior to medium-dose group（P〈0.05）,medium-dose group was superior to low-dose group（P〈0.05）.Conclusion：Cerebroprotein hydrolysate can improve the curative effect of acute cerebral infarction.And,within a certain range of doses,efficacy is positively correlated with the dose.